Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced that it will release its second quarter 2023 financial results on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss its financial and operational results.
Interested parties can pre-register for the call using the provided link. A replay of the conference call will be available until Thursday, August 22, 2024. The webcast can be accessed through the 'Events' section on the company's investor relations page or via the provided link.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2023 il giovedì 8 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda ospiterà una conference call e webcast alle 8:30, ora orientale dello stesso giorno per discutere i suoi risultati finanziari e operativi.
Le parti interessate possono preregistrarsi per la chiamata utilizzando il link fornito. Una registrazione della conference call sarà disponibile fino al giovedì 22 agosto 2024. Il webcast può essere accessibile tramite la sezione 'Eventi' nella pagina di relazioni con gli investitori dell'azienda o tramite il link fornito.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2023 el jueves 8 de agosto de 2024, antes de la apertura de los mercados financieros en EE. UU. La compañía llevará a cabo una conferencia telefónica y transmisión web a las 8:30 a.m. hora del este el mismo día para discutir sus resultados financieros y operativos.
Las partes interesadas pueden preinscribirse para la llamada utilizando el enlace proporcionado. Una repetición de la conferencia telefónica estará disponible hasta el jueves 22 de agosto de 2024. El webcast se puede acceder a través de la sección 'Eventos' en la página de relaciones con los inversores de la compañía o mediante el enlace proporcionado.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS)는 2023년 2분기 재무 결과를 2024년 8월 8일 목요일에 미국 금융 시장이 열리기 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 기준 오전 8시 30분에 재무 및 운영 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
관심 있는 분들은 제공된 링크를 통해 전화를 미리 등록할 수 있습니다. 컨퍼런스 콜의 녹화는 2024년 8월 22일 목요일까지 제공됩니다. 웹캐스트는 회사의 투자자 관계 페이지의 '이벤트' 섹션에서 또는 제공된 링크를 통해 접근할 수 있습니다.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2023 le jeudi 8 août 2024, avant l'ouverture des marchés financiers américains. L'entreprise tiendra une conférence téléphonique et un webcast à 8h30, heure de l'Est le même jour pour discuter de ses résultats financiers et opérationnels.
Les parties intéressées peuvent préinscrire pour l'appel en utilisant le lien fourni. Un enregistrement de la conférence téléphonique sera disponible jusqu'au jeudi 22 août 2024. Le webcast est accessible via la section 'Événements' sur la page des relations avec les investisseurs de l'entreprise ou via le lien fourni.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) hat angekündigt, dass die finanziellen Ergebnisse des zweiten Quartals 2023 am Donnerstag, den 8. August 2024, vor Eröffnung der US-Finanzmärkte veröffentlicht werden. Das Unternehmen wird am gleichen Tag um 8:30 Uhr Eastern Time eine Konferenzschaltung und Webcast abhalten, um über seine finanziellen und operationellen Ergebnisse zu diskutieren.
Interessierte Parteien können sich über den bereitgestellten Link für den Anruf vorregistrieren. Eine Wiederholung des Konferenzgesprächs wird bis Donnerstag, den 22. August 2024 verfügbar sein. Der Webcast kann über den Bereich 'Veranstaltungen' auf der Investor-Relations-Seite des Unternehmens oder über den bereitgestellten Link aufgerufen werden.
- None.
- None.
Conference call and webcast at 8:30am ET
To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=44e9222b&confId=68537 After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, August 22, 2024 at US: 1 929 458 6194, US Toll Free: 1 866 813 9403,
To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/670337574
About Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725635772/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
When will Xeris Biopharma (XERS) release its Q2 2023 financial results?
What time is Xeris Biopharma's (XERS) Q2 2023 earnings call scheduled for?
How long will the replay of Xeris Biopharma's (XERS) Q2 2023 earnings call be available?
Where can I access the webcast for Xeris Biopharma's (XERS) Q2 2023 earnings call?
